drugset / Trial / NCT00113945

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

NCT00113945

Phase 2 Completed 360 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum calcium, serum phosphorus, and calcium phosphorus product.

Timeline

Start
2003-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinacalcet Other / unclassified